AdaptHealth Corp. (NASDAQ:AHCO) Shares Bought by Reinhart Partners LLC.

Reinhart Partners LLC. grew its position in shares of AdaptHealth Corp. (NASDAQ:AHCO - Free Report) by 15.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,236,262 shares of the company's stock after purchasing an additional 969,408 shares during the period. AdaptHealth accounts for about 2.9% of Reinhart Partners LLC.'s investment portfolio, making the stock its 12th largest position. Reinhart Partners LLC. owned about 5.37% of AdaptHealth worth $78,441,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the stock. GAMMA Investing LLC boosted its position in shares of AdaptHealth by 2,883.7% in the first quarter. GAMMA Investing LLC now owns 81,007 shares of the company's stock worth $878,000 after acquiring an additional 78,292 shares during the last quarter. Moody National Bank Trust Division boosted its position in shares of AdaptHealth by 6.3% in the first quarter. Moody National Bank Trust Division now owns 160,759 shares of the company's stock worth $1,743,000 after acquiring an additional 9,589 shares during the last quarter. Mackenzie Financial Corp boosted its position in shares of AdaptHealth by 111.8% in the fourth quarter. Mackenzie Financial Corp now owns 81,583 shares of the company's stock worth $777,000 after acquiring an additional 43,059 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of AdaptHealth by 21.8% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 197,901 shares of the company's stock worth $1,884,000 after acquiring an additional 35,431 shares during the last quarter. Finally, State of Wyoming boosted its position in shares of AdaptHealth by 26.5% in the fourth quarter. State of Wyoming now owns 30,641 shares of the company's stock worth $292,000 after acquiring an additional 6,418 shares during the last quarter. 82.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently commented on AHCO. UBS Group cut their price target on shares of AdaptHealth from $12.00 to $11.00 and set a "buy" rating on the stock in a report on Thursday, February 13th. Robert W. Baird raised their price target on shares of AdaptHealth from $14.00 to $16.00 and gave the company an "outperform" rating in a report on Thursday, February 27th. Canaccord Genuity Group raised their price target on shares of AdaptHealth from $13.00 to $14.00 and gave the company a "buy" rating in a report on Wednesday, February 26th. Truist Financial cut their price target on shares of AdaptHealth from $14.00 to $13.00 and set a "buy" rating on the stock in a report on Monday, May 12th. Finally, Royal Bank of Canada cut their price target on shares of AdaptHealth from $14.00 to $13.00 and set an "outperform" rating on the stock in a report on Thursday, May 8th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $13.40.

AdaptHealth Trading Down 1.3%

AHCO opened at $8.90 on Friday. The firm has a market capitalization of $1.20 billion, a P/E ratio of -5.39, a P/E/G ratio of 1.08 and a beta of 1.64. The firm's 50 day moving average is $8.79 and its 200-day moving average is $9.56. AdaptHealth Corp. has a 52-week low of $7.11 and a 52-week high of $11.90. The company has a quick ratio of 1.00, a current ratio of 1.24 and a debt-to-equity ratio of 1.34.

AdaptHealth Profile

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.